MindMaze Therapeutics Welcomes New CEO

MindMaze Therapeutics Holding SA has a new leader, as the company recently appointed Zach Henderson as CEO.

Henderson joins the company at a pivotal inflection point as MindMaze Therapeutics invests in scaling its existing commercial presence, focused on accelerating the adoption of its U.S. Food and Drug Administration-cleared platform in the United States to address the widening supply-demand gap in neurological care, executives said.

The global healthcare system faces a critical shortage of neurologists and specialized therapists, leaving millions of patients with stroke, Parkinson’s disease, and Alzheimer’s with insufficient access to recovery. MindMaze is redefining this paradigm by shifting care from episodic, clinic-bound sessions to continuous, data-driven neurorestoration accessible at scale in both clinical and home settings.

With more than 30 years of experience, Henderson has scaled healthcare technology platforms and driven significant recurring revenue growth. His most recent role as chief commercial officer at Rune Labs and his prior tenure as CEO of PKG Health and Global Kinetics underscore his expertise in commercializing artificial intelligence (AI)-driven solutions for complex chronic conditions such Parkinson’s disease.

“MindMaze has built the industry’s most rigorous clinical foundation. Our mission now is to translate that scientific leadership into widespread market adoption,” MindMaze Board Chairman Walid Hanna stated. “Zach’s operational depth and success across global markets make him the ideal leader to drive our commercial expansion and deliver value to our shareholders.”

At Global Kinetics, Henderson led the commercialization and global expansion of AI-driven solutions for complex neurological and chronic conditions. Earlier in his career, he held senior leadership roles at public and private healthcare organizations.

Henderson earned an MBA from Villanova University and a bachelor’s degree in finance from Miami University.

“I am honored to lead MindMaze as we solve one of healthcare’s most pressing capacity challenges,” Henderson said. “By digitizing the neuro-restorative journey, we are providing a scalable solution to a global shortage of specialized care providers. We are redefining the standard of care for tens of millions of patients worldwide.”

Alexandre Capet has been appointed chief operating and strategy officer, continuing his service as a standing Executive Committee member.

MindMaze Therapeutics is a global developer of brain technology that aims to redefine the recovery trajectory for patients with neurological platform-based digital treatments. By integrating advanced software, proprietary sensors, and AI-driven data analytics, MindMaze Therapeutics provides a seamless continuum of care from the acute hospital phase to outpatient treatment to the home-based therapy. The company’s U.S. Food and Drug Administration-cleared and CE-marked neurotherapeutics address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson’s disease, and other brain disorders. With a commitment to rigorous clinical validation and a robust R&D pipeline, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.